Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Aric Orbach"'
Autor:
Ralph Laufer, Spyros Papapetropoulos, Michael Hill, Paula Ravenscroft, Lilach Steiner, Jonathan M. Brotchie, Susan H. Fox, Juha-Matti Savola, Aric Orbach, Ian J. Reynolds, Tom H. Johnston, Michal Geva, Michael R. Hayden
Publikováno v:
Movement Disorders. 34:708-716
BACKGROUND Pridopidine, in development for Huntington's disease, may modulate aberrant l-dopa-induced effects including l-dopa-induced dyskinesia (LID). OBJECTIVE This study investigated whether pridopidine could reduce LID in the MPTP macaque model
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db669eaf62b3465b6904bcf66c243d62
https://doi.org/10.1002/mds.27565
https://doi.org/10.1002/mds.27565
Autor:
Aric Orbach, Tuukka O. Piiponniemi, Anna-Mari Karkkainen, Ari Suhonen, Joel Kaye, Kimmo Lehtimäki, Markku Forsman, Juho Koponen, Pavlina Pavlidi, Maksym V. Kopanitsa, Artem Shatillo, Patrick J. Sweeney, Antti Nurmi, Avia Merenlender‐Wagner
Publikováno v:
Genes, Brain and Behavior. 20
Cognitive problems frequently accompany neurological manifestations of multiple sclerosis (MS). However, during screening of preclinical candidates, assessments of behaviour in mouse models of MS typically focus on locomotor activity. In the present
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f43ebe1904ad6191f62c01c1d93a86ce
https://doi.org/10.1111/gbb.12663
https://doi.org/10.1111/gbb.12663
Autor:
Liang Juin Tan, Michael R. Hayden, Rebecca Kusko, Iris Grossman, Yoonjeong Cha, Xiaohong Xu, Marta Garcia-Miralles, Mahmoud A. Pouladi, Jing Ying Tan, Nur Amirah Binte Mohammad Yusof, Aric Orbach, Michal Geva
Publikováno v:
JCI Insight. 2
Pridopidine is currently under clinical development for Huntington disease (HD), with on-going studies to better characterize its therapeutic benefit and mode of action. Pridopidine was administered either prior to the appearance of disease phenotype
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e9412880d43660bd36e8cd29519a125
https://doi.org/10.1172/jci.insight.95665
https://doi.org/10.1172/jci.insight.95665
Autor:
Deog Joong Kim, Ietje Kathmann, Young Bok Lee, Chang-Ho Ahn, Godefridus J. Peters, Aric Orbach, Leonardo Vecchi, Nienke Losekoot, Kees Smid, Richard J. Honeywell, Eran Blaugrund, Osnat Ohne, Lak Shin Jeong, Dzjemma Sarkisjan
Publikováno v:
Peters, G J, Smid, K, Vecchi, L, Kathmann, I, Sarkisjan, D, Honeywell, R J, Losekoot, N, Ohne, O, Orbach, A, Blaugrund, E, Jeong, L S, Lee, Y B, Ahn, C H & Kim, D J 2013, ' Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360) ', Investigational New Drugs, vol. 31, no. 6, pp. 1444-1457 . https://doi.org/10.1007/s10637-013-0025-x
Investigational New Drugs, 31(6), 1444-1457. Kluwer Academic Publishers
Investigational New Drugs, 31(6), 1444-1457. Kluwer Academic Publishers
A novel cytidine analog fluorocyclopentenylcytosine (RX-3117; TV-1360) was characterized for its cytotoxicity in a 59-cell line panel and further characterized for cytotoxicity, metabolism and mechanism of action in 15 additional cancer cell lines, i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6007e50d218b698c53464fa972777893
https://doi.org/10.1007/s10637-013-0025-x
https://doi.org/10.1007/s10637-013-0025-x
Autor:
Rina Kashi, Aric Orbach, Victor Piryatinsky, Daphna Laifenfeld, Mark A. Ator, Tal Birnberg, Doron Shinar, Tal Hingaly, Efrat Rubinstein, Emanuel Raymond, Einat Amit-Romach, Fadi Towfic, Ralph Laufer, Yael Marantz, Iris Grossman, Joel Kaye, Ignacio S. Caballero, Volker Knappertz, Michael R. Hayden
Publikováno v:
Proceedings of the National Academy of Sciences. 113
Laquinimod is an oral drug currently being evaluated for the treatment of relapsing, remitting, and primary progressive multiple sclerosis and Huntington’s disease. Laquinimod exerts beneficial activities on both the peripheral immune system and th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4490b19826a5e659a49611d62f383741
https://doi.org/10.1073/pnas.1607843113
https://doi.org/10.1073/pnas.1607843113
Autor:
Fadi Towfic, Aric Orbach, Steve Barash, Yoonjeong Cha, Tal Birnberg, Avia Merenlender Wagner, Andrew C. Lysaght, Ben Zeskind, Tania Fine, Rebecca Kusko, Michal Geva, Sarah Kolitz, Michael R. Hayden, Brian Weiner, Holly Soares, Iris Grossman, Kevin D. Fowler, Ralph Laufer
Publikováno v:
Human Molecular Genetics
Pridopidine has demonstrated improvement in Huntington Disease (HD) motor symptoms as measured by secondary endpoints in clinical trials. Originally described as a dopamine stabilizer, this mechanism is insufficient to explain the clinical and precli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd7194142aa4c5db7b2ae2053740bb66
https://pubmed.ncbi.nlm.nih.gov/27466197
https://pubmed.ncbi.nlm.nih.gov/27466197
Autor:
Leonardo Vecchi, Young Bok Lee, Godefridus J. Peters, Chang-Ho Ahn, Osnat Ohne, Kees Smid, Lak Shin Jeong, Eran Blaugrund, Deog Joong Kim, Ietje Kathmann, Aric Orbach, Nienke Loosekoot
Publikováno v:
Cancer Research. 72:1770-1770
Cytidine analogs play an important role in the treatment of various types of cancer, both solid tumors and leukemia. A novel cytidine analog fluorocyclopentenylcytosine (RX-3117) was characterized for its cytotoxic effects, its metabolism and its mec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f6fe08761d67409278d25531e0ef234
https://doi.org/10.1158/1538-7445.am2012-1770
https://doi.org/10.1158/1538-7445.am2012-1770